Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Current Deferred Revenue (2016 - 2025)

iBio (IBIO) has disclosed Current Deferred Revenue for 10 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 91.67% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 91.67% increase, with the full-year FY2025 number at $1.2 million, up 500.0% from a year prior.
  • Current Deferred Revenue was $1.2 million for Q4 2025 at iBio, roughly flat from $1.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.2 million in Q2 2025 to a low of $8000.0 in Q1 2022.
  • A 4-year average of $455937.5 and a median of $300000.0 in 2024 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 99.1% in 2022, then surged 500.0% in 2025.
  • iBio's Current Deferred Revenue stood at $60000.0 in 2021, then skyrocketed by 46.67% to $88000.0 in 2022, then soared by 581.82% to $600000.0 in 2024, then surged by 91.67% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Current Deferred Revenue are $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025).